TNFRSF17
TNF Receptor Superfamily Member 17 (TNFRSF17): A Gateway to Immunomodulation and Disease
Description
TNFRSF17, also known as BCMA (B-cell maturation antigen), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). It is expressed primarily on mature B cells and plays a crucial role in B cell survival, differentiation, and antibody production.
TNFRSF17 is a type III transmembrane protein that binds to two ligands: B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL). Upon ligand binding, TNFRSF17 undergoes conformational changes that trigger intracellular signaling cascades, leading to cell survival, proliferation, and differentiation.
Associated Diseases
Dysregulation of TNFRSF17 signaling has been linked to several diseases, including:
- Multiple myeloma (MM): TNFRSF17 is overexpressed in MM cells, contributing to their survival and proliferation. Targeting TNFRSF17 with antibodies has emerged as a promising treatment strategy for MM.
- Autoimmune diseases: TNFRSF17 promotes B cell differentiation and antibody production. Its dysregulation can lead to excessive antibody production and autoimmune disorders such as rheumatoid arthritis and lupus.
- Chronic lymphocytic leukemia (CLL): TNFRSF17 is expressed on CLL cells and contributes to their resistance to apoptosis. Inhibition of TNFRSF17 signaling has shown potential in treating CLL.
- Inflammatory bowel disease (IBD): TNFRSF17 is involved in the regulation of intestinal inflammation. Dysregulation of TNFRSF17 signaling has been associated with both Crohn's disease and ulcerative colitis.
Did you Know ?
- TNFRSF17 is estimated to be overexpressed in up to 80% of multiple myeloma patients, highlighting its importance as a therapeutic target.
